About Mitochondrial Medicine 2024 and Continuing Medical Education

On June 26-29, 2024, the United Mitochondrial Disease Foundation (UMDF) hosted Mitochondrial Medicine 2024 (MitoMed24) - This was a four-day scientific meeting conference directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program has been determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, and new medical knowledge.  

Select courses from MitoMed2024 have been made available for Continuing Medical Education credits as enduring material. The UMDF proudly hosts annual conferences, bringing together the mitochondrial medicine community. For more information about UMDF and the next UMDF Mito Med conference, visit www.umdfconference.org.

Continuing Medical Education Course Information

 

COURSE DESCRIPTION

The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited activity. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS, diabetes and autism.  This live meeting is directed toward the scientist and clinician interested in obtaining a comprehensive update on mitochondrial medicine. The format will include didactic lectures from invited experts intermixed with rigorous discussion. There will be ample time for questions and answers throughout the program. 

 

TARGET AUDIENCE

Neurologists, Geneticists, Researchers/Scientists, Pediatrics, Internal Medicine, Nephrologists, Cardiologists, Endocrinologists, Genetic Counselors, Advanced Practice Nurses, Physicians Assistants, RNs, Occupational Therapy, Physical Therapy and Speech-Language Pathology, Nutritional Therapy, and Residents/Fellows/Students.

 

ACCREDITATION AND DESIGNATION STATEMENTS

Live Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Enduring Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Live activity dates: June 26 to June 29, 2024

Enduring activity dates: October 28, 2024 – October 28, 2027


LEARNING OBJECTIVES

Platform Session 1 (morning) - Advances in Disease Models for Investigating Mitochondrial Diseases

  1. Knowledge: Explain the role of mitochondrial double-stranded RNA as a Damage-Associated Molecular Pattern (DAMP) and its activation of the immune response in mitochondrial diseases, demonstrating an understanding of innate immune mechanisms.
  2. Application: Assess the utility of pluripotent stem cells and brain organoids in drug discovery for mitochondrial diseases, identifying their potential for modeling disease pathology and aiding in therapeutic development.

 

Platform Session 2 (afternoon) - Mitochondria and Metabolic Plasticity

  1. Comprehension: Differentiate between metabolic causes of mitochondrial myopathy and evaluate available tools for their treatment, emphasizing the significance of metabolic interventions in managing mitochondrial disorders.
  2. Analysis: Analyze the impact of mitochondrial metabolism on neutrophil fate and cellular state transitions, emphasizing the interconnectedness of mitochondrial function and cellular physiology.

Platform Session 3 (morning) - Disorders of Mitochondrial DNA Integrity

  1. Understanding: Explain the mechanisms and causes of mtDNA deletions, differentiating between disorders such as Pearsons/Kearns-Sayre Syndrome (KSS) and Chronic Progressive External Ophthalmoplegia (CPEO) Spectrum Disorder.
  2. Application: Evaluate gene editing therapies, such as PBGENE-PMM, for shifting heteroplasmy in m.3243A>G-associated mitochondrial myopathy, demonstrating an understanding of novel approaches for treating mitochondrial DNA integrity disorders.

Platform Session 4 - Development of Improved Outcome Measures for Mitochondrial Clinical Trials

  1. Analysis: Assess the validity and reliability of multi-domain responder indices and digital wearables as outcome measures in mitochondrial clinical trials, highlighting their utility in evaluating treatment efficacy.
  2. Application: Develop a novel outcome measure for rare pediatric neuromuscular diseases, considering the specific challenges and characteristics of mitochondrial diseases, showcasing an ability to adapt measurement tools to unique patient populations.

Platform Session 6 - Mitochondrial Dysfunction and its Impact on Mental Health

  1. Understanding: Correlate mitochondrial dysfunction with psychiatric presentations and mental illness, demonstrating an understanding of the interplay between mitochondrial function and mental health.
  2. Synthesis: Develop a comprehensive perspective on the elevated risk of treatment-emergent mania in individuals with mitochondrial dysfunction, integrating knowledge from various presentations to understand the broader impact on mental health.

Platform Session 7 - Therapeutic Development for Mitochondrial Disease: Lessons learned from other Rare Diseases

  1. Application: Apply insights from the drug approval journeys in other rare diseases, such as SMA, Barth syndrome, Friedreich's ataxia, and metabolic disorders, to inform therapeutic development strategies for mitochondrial diseases.
  2. Evaluation: Critically assess post-approval challenges in drug development for rare diseases, emphasizing lessons learned and potential strategies to overcome hurdles in the therapeutic landscape for mitochondrial diseases.